Background:The abnormal expression of small G protein signaling modulator 2 (SGSM2)
is related to the occurrence of thyroid cancer and breast cancer. However, the role of SGSM2
in uveal melanoma (UVM) is unclear.Objects:To elucidate this ambiguity, our study utilized bioinformatics analysis and experimental
validation.Methods:The expression of SGSM2 was detected in UVM cell lines through quantitative real--
time PCR (qRT-PCR). We utilized the Cancer Genome Atlas (TCGA) database to assess the relationship
between SGSM2 expression and clinical characteristics, as well as its prognostic significance
in UVM. Furthermore, the study examined potential regulatory networks involving SGSM2
in relation to immune infiltration, immune checkpoint genes, microsatellite instability (MSI), and
drug sensitivity in UVM. The study also examined SGSM2 expression in UVM single-cell sequencing
data.Results:SGSM2 was highly expressed in UVM cell lines. Moreover, elevated levels of SGSM2
in UVM patients were significantly linked to poorer overall survival (OS) (p < 0.001), progress-
free survival (PFS) (p < 0.001), and disease-specific survival (DSS) (p < 0.001). Additionally,
SGSM2 expression was identified as an independent prognostic factor in UVM patients (p <
0.001). SGSM2 was associated with several pathways, including the calcium signaling pathway,
natural killer cell-mediated cytotoxicity, cell adhesion molecules (CAMs), and others. The study
revealed that SGSM2 expression in UVM is linked to immune infiltration, immune checkpoint
genes, and MSI. Additionally, a significant inverse correlation was observed between SGSM2 expression
and the compounds GSK690693, TL-2-105, PHA-793887, Tubastatin A, and SB52334 in
UVM patients.Conclusion:SGSM2 may not only serve as an important indicator for prognostic assessment.
Still, it may also be a key target for the development of new therapeutic approaches, providing
new perspectives on the treatment of UVM patients.